Abstract
Introduction
Insulin resistance (IR) could be regarded as a therapeutic target for metabolic diseases. Therefore, multiple therapeutic strategies that target IR should be applied to provide a more effective means of treatment. It aims to determine Tuina’s efficacy and safety for IR through this systematic review and meta-analysis.
Methods
From the inception to July 31, 2023, we will search four English databases (Pubmed, Embase, Cochrane Central Register of Controlled Trials, Web of Science) and two Chinese databases (China National Knowledge Infrastructure and the Chinese Science and Technology Periodical Database). We will search and include studies of both human and animal models that evaluate Tuina’s effects on insulin sensitivity or resistance. Data selection, data extraction, and risk of bias assessment will be made by two independent reviewers. We will evaluate the methodological quality of all included studies and conduct meta-analyses using Review Manager Software 5.4.1.
Discussion
In both animal and human studies, the effects and safety of Tuina for IR will be evaluated. The evidence generated bythis study will validate effects and safety of Tuinain treating IR and inform future research and clinical decision-making.
Trail registration
PROSPERO Registration ID: CRD42022360128.
Funder
Heilongjiang Provincial Administration of Traditional Chinese Medicine
State Administration of Traditional Chinese Medicine of People’s Republic of China
Publisher
Public Library of Science (PLoS)